Navigation Links
CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
Date:1/30/2008

PALO ALTO, Calif., Jan. 30 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that it will release fourth quarter and year end financial results for 2007 after the market closes on Tuesday, February 26, 2008. Company management will webcast a conference call at 5:00 p.m. EST, 2:00 p.m. PST, on the company's website.

To access the live webcast, please log on to the Company's website at http://www.cvt.com and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6247, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Tuesday, March 4, 2008. Domestic callers can access the replay by dialing (800) 642-1687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 32378484.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, i
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
2. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
3. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
5. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
6. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
7. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
8. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
9. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
10. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
11. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... yields to disease risks, the biological characteristics people care ... as for heightthe textbook example of a complex traitattributes ... by multiple genetic and environmental influences, making it challenging ... genes, geneticists typically mate two individuals that differ in ... mouseand then study their descendents, looking for genes that ...
(Date:9/19/2014)... to move data would consume much less power ... as chips, transistor counts rise. , Of the ... emitters, modulators, and detectors emitters are the ... optical chips is molybdenum disulfide (MoS2), which has ... atom-thick layer. Other experimental on-chip light emitters have ...
(Date:9/19/2014)...  An entire month is dedicated to one of ... disease (CMT) – a debilitating neuromuscular disease affecting the ... weakness, and foot and hand deformities. CMT affects 1 ... is a progressive disease, and over time patients lose ... such as leg braces, wheelchairs and scooters to get ...
(Date:9/19/2014)... FRANCISCO , Sept. 19, 2014  Nektar ... results from preclinical studies characterizing the analgesic profiles ... peripherally-acting kappa opioid receptor agonist molecules. The preclinical ... polymer medicinal chemistry platform. The analgesic ... in the medical literature. 1,2 Kappa opioid ...
Breaking Biology Technology:Want to link genes to complex traits? Start with more diversity 2Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... leading provider of room-temperature biosample transport, storage and ... 3.2, the newest version of its software for ... include a strategic licensing model that enables GenConnect ... as well as a new customer licensing model ...
... Crystal Research Associates, LLC announced today that it ... Biotech, Inc. The full 56-page report can be found ... Biotech" or "the Company") is a closely held pharmaceutical ... novel cancer therapeutics. Following a technology spinout from Bayer ...
... Conference Call and Webcast to FollowTHE WOODLANDS, Texas, April ... ) will release its first quarter 2009 financial results ... open. Lexicon management will hold a conference call ... for first quarter 2009 at 11:00 a.m. Eastern Time ...
Cached Biology Technology:GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2 2GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2 3Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 2Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 3Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009 2
(Date:9/18/2014)... New research has found clownfish larvae can swim up to ... better able to cope with environmental change. , Clownfish spend ... anemone but as babies they must wander the open ocean, ... of Excellence for Coral Reef Studies (Coral CoE) at James ... they go, but now we,ve been given a rare glimpse ...
(Date:9/17/2014)... of the Santa Ana Wildfire Threat Index a ... the powerful, hot, dry Santa Ana wind, which can ... introduced Sept. 17 by the U.S. Forest Service, in ... , The index includes four classification levels ranging from ... fire agencies and other emergency responders, the media and ...
(Date:9/17/2014)... in 2000 as an EC-FP5 four-year project, delivering its ... progress and successful participations in several EC projects, as ... Network project (EU BON), to increase the general ... to extend the general dissemination of the Fauna Europaea ... has applied its novel e-Publishing tools to prepare data ...
Breaking Biology News(10 mins):Nemo's epic journey to find a new home 2UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... San Francisco A human monoclonal antibody developed ... (UMMS) given to patients with chronic hepatitis C virus ... for at least a week after transplant and delayed ... double-blind, placebo-controlled, phase 2 study were presented this week ...
... the nature of crowds playing Foldit called some strategies ... methods already used by protein scientists., Gamers made headlines ... central to research on AIDS. Today, in a ... National Academy of Sciences, University of Washington researchers ...
... CORONA, Calif., Nov. 7, 2011 AVT, Inc. (formerly ... partnered with MedBox to provide a new line of ... Fingerprint Recognition System. This new system provides ... and verification of the customer is critical. ...
Cached Biology News:Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients 2Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients 3Paper uncovers power of Foldit gamers' strategies 2Paper uncovers power of Foldit gamers' strategies 3AVT Partners with MedBox to Provide New Biometric Fingerprint Recognition for Secure Automated Retailing 2
... Gel-Digesting Preparation contains a unique β-agarose digesting ... recovery of intact DNA and RNA from ... electrophoresis in TAE, TBE, MOPS, or phosphate ... in the TAE, TBE, MOPS, and phosphate ...
Request Info...
... Electron RapidStak provides valuable walk-away time and ... buffer nest technology for parallel processing of ... fast, reliable automation for any laboratory in ... The RapidStak can be set-up within minutes ...
... Benzonase Nuclease is a genetically engineered endonuclease. ... DNA and RNA while having no proteolytic ... range of conditions and possesses an exceptionally ... nucleic acids from recombinant proteins, its use ...
Biology Products: